RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteShanghai Chest Hospital上海市胸科医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06430437, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients with histologically or cytologically confirmed advanced or metastatic NSCLC.

    Inclusion criterion 4

  3. ECOG score of 0 or 1.

    Inclusion criterion 3

  4. Have at least one measurable lesion outside the central nervous system that meets the criteria defined by RECIST v1.1

    Inclusion criterion 7

  5. Mixed lung cancer with small cell components and sarcomatoid carcinoma confirmed by histology or cytology.

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06430437, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Able and willing to provide a written informed consent
  • 18-75 years old (inclusive of both ends)
  • ECOG score of 0 or 1.
  • Patients with histologically or cytologically confirmed advanced or metastatic NSCLC.
  • Subjects with central laboratory- confirmed functional HER2 mutations
  • No prior systemic antitumor therapy (including investigational agents) for advanced or metastatic NSCLC.
  • Have at least one measurable lesion outside the central nervous system that meets the criteria defined by RECIST v1.1
  • Protocol-defined adequate organ function including cardiac, renal, hepatic function

Exclusion Criteria:

  • Mixed lung cancer with small cell components and sarcomatoid carcinoma confirmed by histology or cytology.
  • Concurrently carrying other driver gene mutations, and targeted drugs for such driver gene mutations have been approved for market release.
  • Subjects with untreated or active metastasis of central nervous system (CNS) tumors, or a history of meningeal metastasis or current meningeal metastasis.
  • With poorly controlled tumor-related pain.
  • previous or current with other malignancies.
  • Subjects with a history of interstitial pneumonia/non-infectious pneumonia requiring hormone therapy, or current interstitial pneumonia/non-infectious pneumonia.
  • Subjects with active or previous autoimmune diseases.
  • Subjects with uncontrolled or severe cardiovascular diseases.
  • Subjects with active hepatitis B or hepatitis C.

Quoted from ClinicalTrials.gov, NCT06430437, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06430437, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06430437